Overview of FDA Expedited Development and Approval Programs for Serious Conditions
Impact Pharmaceutical Services
MAY 4, 2022
These programs are intended to facilitate and expedite development and ensure that therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies’ benefits justify their risk. Image courtesy of geralt at pixabay.com. Category: Regulatory Affairs , Drug Development Consulting.
Let's personalize your content